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Objectives The study investigated the long-term clinical impact of sirolimus-eluting stents (SES) in comparison with bare-
metal stents (BMS) in treatment of focal infrapopliteal lesions.
Background There is evidence that SES reduce the risk of restenosis after percutaneous infrapopliteal artery revasculariza-
tion. No data from randomized trials are available concerning the clinical impact of this finding during long-term
follow-up.
Methods The study extended the follow-up period of a prospective, randomized, multicenter, double-blind trial comparing
polymer-free SES with placebo-coated BMS in the treatment of focal infrapopliteal de novo lesions. The main
study endpoint was the event-free survival rate defined as freedom from target limb amputation, target vessel
revascularization, myocardial infarction, and death. Secondary endpoints include amputation rates, target vessel
revascularization, and changes in Rutherford-Becker class.
Results The trial included 161 patients. The mean target lesion length was 31  9 mm. Thirty-five (23.3%) patients died
during a mean follow-up period of 1,016  132 days. The event-free survival rate was 65.8% in the SES group
and 44.6% in the BMS group (log-rank p  0.02). Amputation rates were 2.6% and 12.2% (p  0.03), and tar-
get vessel revascularization rates were 9.2% and 20% (p  0.06), respectively. The median (interquartile range)
improvement in Rutherford-Becker class was –2 (–3 to –1) in the SES group and –1 (–2 to 0) in the BMS group,
respectively (p  0.006).
Conclusions Long-term event-free survival, amputation rates, and changes in Rutherford-Becker class after treatment of focal
infrapopliteal lesions are significantly improved with SES in comparison with BMS. (YUKON-Drug-Eluting Stent
Below the Knee - Randomised Double-Blind Study [YUKON-BTX]; NCT00664963) (J Am Coll Cardiol 2012;60:
587–91) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.035Greater life expectancy and the increasing prevalence of
diabetes mellitus in developed countries lead to a progres-
sively rising number of patients with critical limb ischemia
(CLI) and intermittent claudication (IC) due to infrapop-
liteal artery (IPA) disease (1).
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provement in Rutherford-Becker
class (2–5). However, none of
these studies confirm an advantage
of SES regarding amputation
rate, limb salvage, and mortality.
Moreover, due to the fact of
higher costs and inconclusive ev-
idence from nonrandomized,
single-center studies advocating
a clinical impact of SES in a
long-term follow-up, PTA and
BMS potentially remain the gold
standard in treatment of focal
IPA lesions (6,7).
To gain more evidence regard-
ing the clinical impact of SES
placement in treatment of IPA
lesions, the follow-up period of a
prospective, double-blind, ran-
domized, multicenter trial comparing polymer-free SES
with BMS was extended. This trial confirms significantly
higher patency rates and greater improvement in Rutherford-
Becker class in patients treated with SES in comparison with
BMS. No significant difference could be observed concern-
ing limb salvage rate, target lesion revascularization, and
event-free survival 1 year after index procedure (5).
Methods
Patient selection and study design. Between April 2006
and April 2008 CLI and IC patients were enrolled in this
prospective, randomized, double-blind trial. Patients were
eligible for the study if they were at least 21 years old, were
not pregnant, and suffered from peripheral artery disease
Rutherford-Becker class of 3 to 5. Angiographic eligibility
criteria were the presence of a single de novo lesion in an
IPA that did not exceed 45 mm in length. We allocated
patients to the 2 treatment groups (polymer-free SES and
BMS) using a computer-generated random sequence. All
patients received aspirin (100 mg daily) and clopidogrel
(loading dose of 600 mg before the procedure followed by
75 mg daily for 6 months). Study design, study procedures,
and 1-year results of this trial were published (5).
After completion of the 1-year results the extension of the
follow-up period was approved by the ethics committee on
August 12, 2011. All patients gave written informed consent.
Follow-up. Clinical follow-up was obtained through out-
patient visits, direct phone call assessments, and correspon-
dence with the primary physician with attention directed to
a questionnaire regarding the clinical course of each patient
including target limb major and minor amputation, TVR,
myocardial infarction, and causes of death. In addition, in
patients who were willing and capable a determination of
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
CLI  critical limb
ischemia
HR  hazard ratio
IC  intermittent
claudication
IPA  infrapopliteal
arteries
PTA  percutaneous
transluminal balloon
angioplasty
SES  sirolimus-eluting
stent(s)
TVR  target vessel
revascularizationthe Rutherford-Becker class was performed.Study endpoints. The main study endpoint was the event-
free survival rate defined as freedom from TVR, major and
minor target limb amputation, myocardial infarction, and
death. Secondary endpoints included amputation rate, TVR,
and change in Rutherford-Becker class. All events were deter-
mined cumulatively for the 1,100 days after stent placement.
Statistical analysis. Data for all endpoints were evaluated in
the intention-to-treat analysis. Continuous data are expressed
as mean  SD. Categorical variables were compared with the
se of the 2-sided chi-square test and continuous variables were
ompared with the use of the 2-sided Student t test. Changes
in Rutherford-Becker class were expressed as median with
interquartile range, and group comparisons were performed
using the Mann-Whitney U test. Event-free survival was
ompared by Kaplan-Meier analysis with the use of the
antel-Cox log-rank. A 2-sided p value 0.05 was consid-
red to indicate statistical significance. To summarize differ-
nces in the primary endpoint between the study groups, we
erived hazard ratios (HR) with associated 95% confidence
ntervals (CI) from the Cox proportional hazards model. To
ssess the interaction of stent type with stage of disease (CLI or
C) and to adjust for remaining imbalance, we performed Cox
egression analyses. In addition to the interaction term, the
ultivariable models included demographic, clinical, and in-
erventional variables (Table 1) with a difference between the 2
tudy groups at a value of p 0.1. All statistical analyses were
erformed with the SPSS software, version 18.0 (SPSS Inc.,
hicago, Illinois).
esults
atient characteristics. At baseline 161 patients were in-
luded in this trial. Eighty-two patients were randomly
ssigned to receive the polymer-free SES, and 79 were
Baseline Characteristics of the OverallP ti nt Popul tion and of Each Treatment Group*Table 1 B seline Charact ristics of the OverallPatient Population and of Each Treatment Group*
All
Patients
(N  161)
SES
(n  82)
BMS
(n  79)
Age, yrs 72.9 9 73.4 8 72.3 9
Male, % 66.5 67.9 64.9
Body mass index, kg/m2 27 4 28 5 27 4
Diabetes mellitus, % 53.8 56.8 50.6
Dyslipidemia, % 76.6 76.5 76.6
Hypertension, % 89.9 91.4 88.3
Current smoker, % 28.5 28.4 28.6
Renal insufficiency, %
(creatinine 1.5 mg/dl)
35.4 35.8 35.1
Critical limb ischemia,† % 46.6 51.2 41.8
Target lesion, %
Anterior tibial artery 27 22 31
Tibioperoneal trunk 37 42 33
Peroneal artery 21 19 23
Posterior tibial artery 15 17 13
Values are mean SD or %. *There were no significant differences between the treatment groups
except for body mass index (p  0.004). †Critical limb ischemia was defined according to the
Rutherford-Becker classification.
BMS  bare-metal stent(s); SES  sirolimus-eluting stent(s).
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cantly higher body mass index in the SES group, the 2
groups were similar with respect to all baseline variables. A
total of 155 patients (96.3%) had 0 or just 1 patent IPA to
the ankle joint (SES group, 95.1%; BMS group, 96.2%; p
0.9) at baseline (Table 1).
Long-term clinical follow-up. The mean follow-up time
was 1,005  139 days in the SES group and 1,027  123
days in the BMS group (p 0.38). Concerning the primary
endpoint, event-free survival rate compared by Kaplan-
Meier analysis was 65.8% in the SES group and 44.6% in
the BMS group (p  0.02) (Fig. 1). Thus, in comparison
with SES, BMS placement was associated with a HR for
adverse events of 1.8 (95% CI: 1.1 to 2.9; p  0.02). The
higher risk of adverse event occurrence associated with BMS
prevailed after adjustment for renal insufficiency, CLI, and
body mass index. The corresponding adjusted HR was 1.7
(95% CI: 1.1 to 2.8; p  0.03). No significant interaction
(p  0.29) could be observed between stent type (SES or
BMS) and stage of disease (CLI and IC) regarding the
primary endpoint when added to the Cox regression model.
The impact of the SES on the incidence of adverse events in
various subgroups of patients is presented in Figure 2.
Seventeen patients (22.6%) in the SES group and 18
patients (24%) in the BMS group (p  0.84) died during
follow-up. Thirteen patients (8.6%) died because of major
cardiac events (myocardial infarction, heart failure). Seven
patients (4.6%) died in consequence of gastrointestinal and
Figure 1 Event-Free Survival in the SES and BMS Groups
Survival free from target vessel revascularization, major and minor amputation,
myocardial infarction, and death was compared by Kaplan-Meier analysis with
the use of the Mantel-Cox log-rank test. BMS  bare-metal stent(s); SES 
sirolimus-eluting stent(s).pulmonary infections or cancer. In 15 patients (10%) the
cause of death remained uncertain. Ten (6.2%) patients (6
in the SES group and 4 in the BMS group; p  0.75) were
lost to follow-up.
Freedom from any target limb amputation was docu-
mented in 97.4% in the SES group and 87.8% in the BMS
group (p 0.03). Limb salvage rates were 98.7% and 94.6%
(p  0.17), respectively.
Clinically driven (recurrent symptoms of IC and/or
worsening skin lesion) TVR was performed in 7 patients
(9.2%) in the SES group and in 15 patients (20%) in the
BMS group (p  0.06). The median (interquartile range)
improvement in Rutherford-Becker class was –2 (–3 to
–1) and –1 (–2 to 0; p  0.006), respectively (Table 2).
Long-term clinical follow-up in patients with CLI and
IC. Concerning patients with CLI event-free survival was
57.9% in the SES group and 32.3% (p  0.07) in the BMS
group (Fig. 3). Amputation was needed in 2 patients treated
with SES (1 major and 1 minor, 5.3%) and in 7 patients
treated with BMS (4 major and 3 minor, 22.6%; p  0.04)
(Table 3).
In patients with IC event-free survival compared by
Kaplan-Meier analysis was 71.1% in the SES group and
50% (p  0.07) in the BMS group, TVR rates were 7.9%
Figure 2 Impact of SES on Adverse Events in Various
Subgroups of Patients
Comparison of the treatment groups concerning the incidence of adverse
events including target vessel revascularization, major and minor
amputation, myocardial infarction, and death by the use of the Cox regression
model. BMI  body mass index; other abbreviations as in Figure 1.and 25% (p  0.04), and changes in Rutherford-Becker
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respectively.
Discussion
To our knowledge, this is the first prospective, randomized,
multicenter study showing favorable clinical outcomes for
SES compared with BMS in IPA application during long-
term follow-up. While PTA and BMS placement provide
Rutherford-Becker Class at Baselineand at Follow-Up of the Overall PatientPopulati n and of Each Treatment Group
Table 2
Rutherford-Becker Cl ss at Baseline
and at Follow-Up of the Overall Patient
Population and of Each Treatment Group
All
Patients SES BMS p Value
Rutherford-Becker Class at Baseline
(N  161) (n  82) (n  79)
2 10 (6.2) 4 (4.9) 6 (7.6)
3 76 (41.8) 36 (43.9) 40 (50.6)
4 9 (5.6) 7 (8.5) 2 (2.5)
5 66 (41) 35 (42.7) 31 (39.3)
Median (IQR) 3 (3 to 5) 4 (3 to 5) 3 (3 to 5) 0.40
Rutherford-Becker Class at Follow-Up
(N  86) (n  44) (n  42)
Median (IQR) 2 (1 to 3) 2 (1 to 3) 2 (2 to 3) 0.02
Improvement by
1 class
62 (72.1) 37 (84.1) 25 (59.5%)
No change 22 (25.6) 7 (15.9) 15 (35.7%)
Worse by 1 class 2 (2.3) 0 (0) 2 (4.8%)
Median change –1 (–3 to 0) –2 (–3 to –1) –1 (–2 to 0) 0.006
Values are n (%) or median (interquartile range [IQR]).
Figure 3 Event-Free Survivals in Patients With
Critical Limb Ischemia in the SES and BMS Groups
Survival free from target vessel revascularization, major and minor amputation,
myocardial infarction, and death was compared by Kaplan-Meier analysis with
the use of the Mantel-Cox log-rank test. Abbreviations as in Figure 1.promising acute procedural results in treatment of IPA the
technical durability is hampered by restenosis rates of more
than 50% after 1 year (2,8,9). There is evidence from
nonrandomized and randomized trials that SES is superior
to PTA and BMS concerning patency rates, TVR, and
improvement in Rutherford-Becker class (2,5,10). How-
ever, no data from randomized studies are available con-
cerning the clinical impact of this finding demonstrating
fewer amputations and higher limb salvage rates after SES
placement in comparison with PTA and BMS.
The present trial reveals that the SES has significant
advantages regarding event-free survival and amputation
rates over BMS. Moreover, significantly greater improve-
ment in Rutherford-Becker class and a clearly lower TVR
rate compared with BMS was noticeable in the long-term
follow-up. No significant interaction was found between
stent type and stage of disease (CLI or IC) concerning the
primary endpoint.
Clinical results in patients with CLI. To date, there are
only few data released from nonrandomized trials regarding
long-term results after treatment of IPA lesions. Moreover,
most of these trials exclusively address CLI patients. There-
fore an accurate comparison with the present trial investi-
gating patients with CLI and IC is restricted. Although the
number of patients included in the present trial limits the
validity of a subgroup analysis limb salvage and mortality
rates of CLI patients treated with BMS are comparable with
the results of CLI patients treated with PTA in former
studies (8,11).
A nonrandomized, single-center study including 106
patients illustrates a limb salvage rate of 94 2% in patients
treated with SES in a 27  19 months follow-up period.
Target limb reintervention was performed in 15% and the
mortality rate was 29% (6). In a prospective registry inves-
tigating the performance of SES versus BMS for CLI at 3
Major Adverse Events and Limb Salvageat F llow-Up in Patients With CriticalLimb Ischemia and Intermit ent Claudication
Table 3
Major Adv rse Events and Limb Salvage
at Follow-Up in Patients With Critical
Limb Ischemia and Intermittent Claudication
Critical Limb Ischemia
SES
(n  38)
BMS
(n  31) p Value
Death 10 (26.3) 10 (32.3) 0.60
Major/minor amputation 1/1 (5.3) 4/3 (22.6) 0.04
TVR 4 (10.5) 4 (12.9) 0.70
Myocardial infarction 0 (0) 2 (6.4) 0.20
Limb salvage 37 (97.4) 27 (87.1) 0.10
Intermittent Claudication
SES
(n  38)
BMS
(n  44)
Death 7 (18.4) 8 (18.2) 1.0
Major/minor amputation 0/0 (0) 0/2 (4.7) 0.19
TVR 3 (7.9) 11 (25) 0.04
Myocardial infarction 1 (2.6) 2 (4.5) 0.50
Limb salvage 38 (100) 44 (100) 1.0
Rutherford-Becker class
Median change (IQR) –2 (–2 to –1) –1 (–1 to 0) 0.03Values are n (%) or median (interquartile range [IQR]).
TVR  target vessel revascularization.
591JACC Vol. 60, No. 7, 2012 Rastan et al.
August 14, 2012:587–91 Sirolimus Stents for Infrapopliteal Diseaseyears a significantly better primary patency (HR: 4.81; 95%
CI: 2.91 to 7.94; p  0.001), and a better intervention-free
survival (HR: 2.56; 95% CI: 1.30 to 5.00; p  0.006) in
patients treated with SES could be observed (7). The
present study reveals comparable results in particular con-
cerning CLI patients treated with SES regarding amputa-
tion rate, TVR rate, and mortality. Moreover, in compari-
son with the BMS group significantly fewer amputations
occur, and a considerably higher limb salvage rate could be
documented in the SES group.
Clinical results in patients with IC. Although it has
become an established treatment for CLI (1,12) endovas-
cular therapy of IPA in patients with IC is not yet accepted
as a therapy option, despite published data underlining the
beneficial clinical effect (13–15). In this context, results of
the present study support findings that the degree of IC is
positively affected by successful and long-lasting interven-
tions of IPA lesions (4,5,16). In addition, compared with
BMS, SES placement in this patient cohort was associated
with a significantly reduced TVR rate and significantly
greater improvement in Rutherford-Becker class.
Study limitations. Changes in quality of life with stan-
dardized questionnaires and possible cost savings by using
drug-eluting stents in IPA lesions needs to be clarified in
upcoming studies.
It must be highlighted that this trial only addresses focal
lesions. Particularly in patients with diabetes and renal
failure the vast majority of IPA lesions appear as diffuse,
long lesions. However, due to the absence of long devices
and restricted applicability in juxta-articular regions (rigid
scaffold of metallic stents) the use of stents (SES) in long
IPA lesions is limited. Moreover, the polymer-free SES
used in the present trial is not available in the United
States. Whether comparable results can be achieved with
next-generation stent devices (with thinner struts, rapa-
mycin analogs) and drug-eluting balloons requires further
investigation.
Conclusions
In a long-term follow-up, this prospective, randomized,
multicenter study demonstrates significantly higher event-
free survival rates and reduced amputation rates after treat-
ment of focal IPA lesions with SES as compared with
treatment with BMS. Both patients with CLI and IC profit
from treatment with SES.
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